Theravance Biopharma, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $350.2M | $344.7M |
| FY2017 | $223.7M | $115.2M | $89.0M |
| FY2018 | $454.4M | $-51.6M | $378.0M |
| FY2019 | $455.0M | $-223.8M | $58.1M |
| FY2020 | $619.2M | $-303.8M | $81.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $350.2M | $344.7M |
| FY2017 | $223.7M | $115.2M | $89.0M |
| FY2018 | $454.4M | $-51.6M | $378.0M |
| FY2019 | $455.0M | $-223.8M | $58.1M |
| FY2020 | $619.2M | $-303.8M | $81.5M |